CrownCast
CrownCast
Podcast Description
CrownCast, Crown Bioscience's podcast aims to discuss the emerging trends,
breakthroughs, and viewpoints in oncology drug discovery, and development.
Podcast Insights
Content Themes
The podcast focuses on critical oncology topics, including drug resistance mechanisms, the impact of artificial intelligence in drug discovery, and the evolving landscape of immuno-oncology. Episodes like 'Pioneering Strategies to Unlocking the Potential of KRAS' and 'Inside Oncology Drug Development: Overcoming Resistance with Science' explore the complexities of KRAS mutations and treatment resistance, while 'Exploring Artificial Intelligence in Drug Discovery' highlights AI's transformative role in R&D processes.

CrownCast, Crown Bioscience’s podcast aims to discuss the emerging trends,
breakthroughs, and viewpoints in oncology drug discovery, and development.
In this CrownCast episode, host Michelle Dawn Mooney speaks with Graham Marsh, Director of the NAMs Developer Coalition at the Critical Path Institute, and Ludovic Bourré, Vice President of Research and Innovation at Crown Bioscience, to explore new approach methodologies (NAMs) and Crown Bioscience’s participation in the coalition. Together, they discuss how patient-derived models, organoids, ex vivo tissue platforms, translational biomarkers, and bioinformatics contribute to the field, and what validation, qualification, and regulatory adoption could mean for practical study design.

Disclaimer
This podcast’s information is provided for general reference and was obtained from publicly accessible sources. The Podcast Collaborative neither produces nor verifies the content, accuracy, or suitability of this podcast. Views and opinions belong solely to the podcast creators and guests.
For a complete disclaimer, please see our Full Disclaimer on the archive page. The Podcast Collaborative bears no responsibility for the podcast’s themes, language, or overall content. Listener discretion is advised. Read our Terms of Use and Privacy Policy for more details.